Drug Interaction Study Between AZD3480 and Cytochrome P450

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of the study is to evaluate if AZD3480 inhibits Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bilirubin; Bupropion; Caffeine; Midazolam; Omeprazole; Rosiglitazone

Criteria

Inclusion Criteria:

• Provision of signed written informed consent

• Clinically normal physical findings and laboratory values

Exclusion Criteria:

• Clinically significant illness or clinically relevant trauma within three weeks before the first dose

• History of clinically significant disease

• Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product